Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Investigational

4

US Approved Rx

3

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Progesterone receptor

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

1

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

4

1959

1

1997

1

2023

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Abnormal uterine bleeding

1

Endometrial cancer

1

Secondary amenorrhea

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Preventing

1

Primary

1

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Syntex

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Protein

5

Chemical

1

Mixture

1

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

7

FDA ORPHAN DRUG

7

FDA UNII

7

NCI_THESAURUS

7

DRUG BANK

6

All Match

Any Match

Exclude Selected

Exclude Selected

Protein Type

MONOCLONAL ANTIBODY

4

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTINEOPLASTIC AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

OTHER ANTINEOPLASTIC AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Monoclonal antibodies

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

6

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Search results for "ORPHAN DRUG|Designated|Treatment of immune thrombocytopenic purpura." in comments (approximate match)

Showing 1 - 7 of 7 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

RILZABRUTINIB

NWN58M4F5T

Status:

Investigational

Class:

MIXTURE

Rozanolixizumab

P7186074QC

Subunit 1 (444) Similarity Search Subunit 2 (444) Similarity Search Subunit 3 (219) Similarity Search Subunit 4 (219) Similarity Search

Export Data
Sequence Search

Subunit 1 (444) Similarity Search Subunit 2 (444) Similarity Search Subunit 3 (219) Similarity Search Subunit 4 (219) Similarity Search

Status:

US Approved Rx (2023)

First approved in 2023

Class:

PROTEIN

RITUXIMAB

4F4X42SYQ6

Subunit 1 (451) Similarity Search Subunit 2 (451) Similarity Search Subunit 3 (213) Similarity Search Subunit 4 (213) Similarity Search

Export Data
Sequence Search

Subunit 1 (451) Similarity Search Subunit 2 (451) Similarity Search Subunit 3 (213) Similarity Search Subunit 4 (213) Similarity Search

Status:

US Approved Rx (2017)

First approved in 1997

Class:

PROTEIN

BEVIFIMOD

PNV0H3A73B

Subunit 1 (423) Similarity Search

Export Data
Sequence Search

Subunit 1 (423) Similarity Search

Status:

Investigational

Class:

PROTEIN

RUPLIZUMAB

562JQF15GN

Subunit 1 (447) Similarity Search Subunit 2 (447) Similarity Search Subunit 3 (218) Similarity Search Subunit 4 (218) Similarity Search

Export Data
Sequence Search

Subunit 1 (447) Similarity Search Subunit 2 (447) Similarity Search Subunit 3 (218) Similarity Search Subunit 4 (218) Similarity Search

Status:

Investigational

Class:

PROTEIN

VELTUZUMAB

BPD4DGQ314

Subunit 1 (451) Similarity Search Subunit 2 (451) Similarity Search Subunit 3 (213) Similarity Search Subunit 4 (213) Similarity Search

Export Data
Sequence Search

Subunit 1 (451) Similarity Search Subunit 2 (451) Similarity Search Subunit 3 (213) Similarity Search Subunit 4 (213) Similarity Search

Status:

Investigational

Class:

PROTEIN

MEDROXYPROGESTERONE ACETATE

C2QI4IOI2G

Export Data
Search for Structure

Status:

US Approved Rx (2022)

First approved in 1959

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Progesterone receptor

Conditions:

Secondary amenorrhea

Abnormal uterine bleeding

Endometrial cancer

Medroxyprogesterone acetate (INN, USAN, BAN), also known as 17α-hydroxy-6α-methylprogesterone acetate, and commonly abbreviated as MPA, is a steroidal progestin, a synthetic variant of the human hormone progesterone. Medroxyprogesterone acetate (MPA)...

administered orally or parenterally in the recommended doses to women with adequate endogenous estrogen, transforms proliferative into secretory endometrium. Androgenic and anabolic effects have been noted, but the drug is apparently devoid of significant estrogenic activity. While parenterally administered MPA inhibits gonadotropin production, which in turn prevents follicular maturation and ovulation, available data indicate that this does not occur when the usually recommended oral dosage is given as single daily doses. MPA is a more potent derivative of its parent compound medroxyprogesterone (MP). While medroxyprogesterone is sometimes used as a synonym for medroxyprogesterone acetate, what is normally being administered is MPA and not MP. Used as a contraceptive and to treat secondary amenorrhea, abnormal uterine bleeding, pain associated with endometriosis, endometrial and renal cell carcinomas, paraphilia in males, GnRH-dependent forms of precocious puberty, as well as to prevent endometrial changes associated with estrogens. Progestins diffuse freely into target cells in the female reproductive tract, mammary gland, hypothalamus, and the pituitary and bind to the progesterone receptor. Once bound to the receptor, progestins slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH surge.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1